Actively Recruiting
CD70-targeted immunoPET Imaging of Kidney Cancer
Led by RenJi Hospital · Updated on 2025-12-31
300
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to establish and optimize the \[18F\]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.
CONDITIONS
Official Title
CD70-targeted immunoPET Imaging of Kidney Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-80 years and of any gender
- Histologically confirmed kidney cancer or suspected kidney cancer by imaging
- Able to provide signed informed consent and comply with study requirements
You will not qualify if you...
- Pregnant women
- Severe liver or kidney failure
- History of serious surgery within the last month
- Allergy to antibody or single-domain antibody radiopharmaceuticals
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China, 200127
Actively Recruiting
Research Team
W
Weijun Wei, Ph.D. & M.D.
CONTACT
W
Wei Zhai, Ph.D. & M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here